This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to derive estimates of effectiveness
The authors made some assumptions, which were used to estimate the disease-specific survival of chemotherapy and PR+C.
Estimates of effectiveness and key assumptions
The mean disease-specific survival was 44 months (median 25) with chemotherapy and 87 months (median 43) with PR+C. This was based on the unproven assumption that chemotherapy provides survival benefits of 12 months with respect to the base-case (no treatment and PR, respectively) in STS metastatic patients.
Measure of benefits used in the economic analysis
The summary benefit measure used in the economic analysis was median survival. This was estimated from the cohort of patients and authors' assumptions. An annual discount rate of 3% was applied.
Direct costs
Discounting was not relevant since all the costs were incurred within the first year of treatment. The unit costs and the quantities of resources used were not reported separately. The health services included in the economic evaluation were chemotherapy and PR, including professional services incurred by the hospital, other in-hospital costs and outpatient visits. The cost/resource boundary of the study was unclear. The costs were estimated using information from the cost accounting system of the University of Texas M D Anderson Cancer Center. Resource use was derived from a different series of patients who were treated at the University of Texas M D Anderson Cancer Center following standard protocols. Some assumptions were made in the cost calculations. All the costs were presented in 2001 values using the medical component of the consumer price index.
CRD COMMENTARY -Selection of comparators
The authors justified the choice of the comparators. Basically, all possible available treatment strategies for STS were covered. PR was selected as trials had shown that it could cure patients with pulmonary metastases. Systemic chemotherapy is a commonly used approach for STS patients, although no study has demonstrated its efficacy. The combination of PR+C was included since this represents a further commonly used treatment strategy. Finally, the no treatment option was considered for comparative purposes. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The analysis of effectiveness was based on a retrospective cohort study. This was used so that clinical data derived from a large series of STS metastatic patients could be included in the analysis. However, as the authors acknowledged, the design is open to the impact of bias and confounding factors, which could not be excluded. The use of a randomised trial would have been more appropriate. Few details of the patients' characteristics were given and the methods used to estimate the clinical outcomes were not reported. Further information can, however, be found elsewhere (Billingsley et al., see Other Publications of Related Interest). Some assumptions, derived from common opinion, were also made. Extensive sensitivity analyses were conducted to investigate variability in the data.
Validity of estimate of measure of benefit
The selection of the benefit measure appears to have been appropriate for assessing the impact of the intervention on the patients' health. Quality of life outcomes were not considered because the retrospective analysis did not permit the assessment of temporal differences in quality of life among strategies. The use of survival permits comparisons with the benefits of other health care technologies. The authors stated that the benefits were discounted, but only undiscounted results were reported.
Validity of estimate of costs
The perspective adopted in the study was not explicitly reported but the authors stressed that true costs, rather than charges or reimbursement rates, were used. The information on the unit costs and the quantities of resources used was unclear. The sources of the cost and resource data were provided. The price year was reported, which facilitates reflation exercises in other settings. The cost estimates were specific to the study setting and no sensitivity analyses of the economic inputs were conducted. The authors noted that the costs might vary in other regions, but the relative differences should be similar. Moreover, the costs were treated deterministically.
Other issues
The authors did not compare their findings with those from other studies. They also did not extensively address the issue of the generalisability of the study results. However, sensitivity analyses were conducted, which enhanced the external validity of the analysis. The authors stressed that their conclusions should be limited to patients with STS pulmonary metastases who could be treated by any of the four strategies considered in the study. The authors highlighted some limitations of their analysis, such as the use of different patient cohorts for clinical outcomes and costs.
Implications of the study
The results of the study supported the therapeutic principle that metastases should be resected whenever possible. The authors suggested that future studies should consider gains in quality of life as well as improvements in survival.
